Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

By J. Schiller, D. Harrington, C. Belani, C. Langer, A. Sandler, J. Krook, Junming Zhu, David H. Johnson. New England Journal of Medicine, 2002

5,023 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/432edd5b661c971e227fdf5629f2e0ce661c2d28

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. William Pao
2. R. Kerbel
3. Vincent A. Miller
4. C. Zappa
5. Shaker A. Mousa
6. K. Kerr
7. M. Hellmann
8. Eric S. Lander

In Pulmonary and Respiratory Medicine

1. William Pao
2. B. Kamen
3. Vincent A. Miller
4. R. Kerbel
5. E. Lengyel
6. J. Massagué
7. N. Ferrara

Citations in the corpus

• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Several platinum-based regimens with third-generation cytotoxics (paclitaxel, gemcitabine, docetaxel, vinorelbine) have shown comparable efficacy [110, 111].”
• Non-small cell lung cancer: current treatment and future advances. (2016, background): “Median overall survival for patients in these studies was approximately 8–10 months (35-38).”
• A molecular signature of metastasis in primary solid tumors (2003, background): “If the presence of the metastasis program in a primary lung tumor is biologically significant, one might expect the clinical outcome of individuals with that gene-expression profile to be worse, as death from lung adenocarcinoma is in most cases attributable to metastasi”
• American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009, background): “As a result of concerns about toxicity and drug tolerance, patients with stage IV NSCLC and PS of 2 have been routinelyexcludedfromprospectivetrialsofnovelcombinationchemotherapy.(61,62) These data provide the foundation for recommending single-agent chemotherapy for patients with PS of 2.”
• The anti-angiogenic basis of metronomic chemotherapy (2004, background): “Despite the number of such chemotherapeutics and the huge number of clinical trials that have been undertaken to test them, progress has been modest in terms of curing or significantly prolonging the lives of patients with cancer — particularly those with advanced-stage or metastatic diseas”